About Lexaria Bioscience Corp.
https://www.lexariabioscience.comLexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery.
CEO
Richard C. Christopher
Compensation Summary
(Year 2009)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-01-12 | Reverse | 1:30 |
| 2015-12-16 | Forward | 11:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
INVENOMIC CAPITAL MANAGEMENT LP
Shares:477.2K
Value:$373.17K
MURCHINSON LTD.
Shares:419.59K
Value:$328.12K
VANGUARD GROUP INC
Shares:258.82K
Value:$202.39K
Summary
Showing Top 3 of 29
About Lexaria Bioscience Corp.
https://www.lexariabioscience.comLexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $174K | $3.92M ▲ | $-3.79M ▼ | -2.18K% ▼ | $-0.21 ▼ | $-3.72M ▼ |
| Q2-2025 | $174K ▼ | $2.93M ▲ | $-2.71M ▼ | -1.56K% ▼ | $-0.15 ▲ | $-2.75M ▼ |
| Q1-2025 | $183.92K ▲ | $2.87M ▲ | $-2.7M ▼ | -1.47K% ▲ | $-0.16 ▲ | $-2.66M ▼ |
| Q4-2024 | $84K | $2.29M ▲ | $-2.18M ▼ | -2.6K% ▼ | $-0.17 ▼ | $-2.2M ▼ |
| Q3-2024 | $84K | $1.83M | $-1.78M | -2.12K% | $-0.13 | $-1.73M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.63M ▼ | $6.74M ▼ | $1.57M ▼ | $5.55M ▼ |
| Q2-2025 | $6.54M ▼ | $8.68M ▼ | $1.92M ▲ | $7.14M ▼ |
| Q1-2025 | $8.12M ▲ | $9.79M ▲ | $399.72K ▼ | $9.77M ▲ |
| Q4-2024 | $6.56M ▼ | $8.87M ▼ | $1.21M ▲ | $8.04M ▼ |
| Q3-2024 | $8.51M | $10.02M | $271.38K | $10.12M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.79M ▼ | $-3.58M ▼ | $-19.44K ▲ | $1.69M ▲ | $-1.88M ▼ | $-3.58M ▼ |
| Q2-2025 | $-2.72M ▼ | $-1.5M ▲ | $-27.89K ▲ | $11.72K ▼ | $-1.61M ▼ | $-1.5M ▲ |
| Q1-2025 | $-2.71M ▼ | $-2.73M ▼ | $-37.8K ▲ | $4.35M ▲ | $1.58M ▲ | $-2.73M ▼ |
| Q4-2024 | $-2.19M ▼ | $-1.89M ▼ | $-69.59K ▼ | $0 ▼ | $-1.96M ▼ | $-1.96M ▼ |
| Q3-2024 | $-1.78M | $-1.27M | $-22K | $5.04M | $3.75M | $-1.29M |
Revenue by Products
| Product | Q1-2025 | Q4-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 B2B | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 IP Licensing | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Richard C. Christopher
Compensation Summary
(Year 2009)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-01-12 | Reverse | 1:30 |
| 2015-12-16 | Forward | 11:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
INVENOMIC CAPITAL MANAGEMENT LP
Shares:477.2K
Value:$373.17K
MURCHINSON LTD.
Shares:419.59K
Value:$328.12K
VANGUARD GROUP INC
Shares:258.82K
Value:$202.39K
Summary
Showing Top 3 of 29